Effect of Mosapride Citrate on Gastrointestinal Motility After Laparoscopic Gastrectomy

Not Applicable

Completed

• Conditions: Stomach Cancer
• Interventions: Drug: Mosapride citrate; Drug: Placebo

• Registration Number: NCT04493125
• Lead Sponsor: Gangnam Severance Hospital

Brief Summary

"Mosapride citrate is a 5-hydroxytryptamine 4 receptor agonist, and is widely used as an agent to increase intestinal motility. Mosapride citrate has been demonstrated in in vitro and in vivo studies to increase both gastric and colon motility. In a case-control study of patients undergoing colonectomy, mosapride citrate was found to significantly reduce gas passing and defecation time.

Recently, a study reported that mosapride citrate acts on the α7nACh receptor and, consequently, suppresses the inflammatory response of macrophages, thereby suppressing the mechanism that induces paralysis after surgery.

To date, this study is intended to analyze whether mosapride citrate significantly affects the improvement of bowel movement after surgery after gastrectomy."

Detailed Description

Not available

Study Timeline

• Study Start: 2020-07-27
• Study First Submitted: 2020-07-28
• Study First Submitted QC: 2020-07-29
• Study First Posted: 2020-07-30
• Primary Completion: 2021-03-30
• Study Completion: 2021-03-30
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-06
• Last Update Posted: 2025-01-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 104

Inclusion Criteria

1. Patients diagnosed with gastric cancer pathologically before surgery
2. Patients who underwent surgical resection (R0 resection)
3. Patients with an ASA score of 3 or less

Exclusion Criteria

1. Patients over 80 years old
2. When there are multiple or peritoneal metastases
3. Intestinal obstruction before surgery
4. When chemotherapy was performed before surgery
5. When cancer other than stomach cancer is diagnosed
6. If you have a long history of major intra-abdominal surgery or a history of abdominal radiotherapy
7. In case of liver failure or kidney failure
8. When it is judged that uncontrolled diabetes may affect intestinal function

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Mosapride group	Mosapride citrate	Patients receive placebo or mosapride citrate (5mg/T) three times a day from the first day after surgery.
Placebo group	Placebo	Patients receive placebo instead of mosapride citrate (5mg/T) three times a day from the first day after surgery

Primary Outcome Measures

Name	Time	Method
The number of radiopaque markers transferred to the large intestine 3 days after surgery	3 Days after surgery	Intestinal motility after gastrectomy

Trial Locations

Locations (1)

GangnamSeverance Hospital; 🇰🇷 Seoul, Korea, Republic of